Bilocor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bilocor

What is Bilocor? Overview

This section defines the identity and classification of the medicinal preparation Bilocor, adhering strictly to its foundational nature and excluding all clinical usage and safety details.

Property Description
Active ingredient Bisoprolol fumarate
Form Film coated tablet (Oral dosage form)
Pharmacological class Cardioselective β₁-adrenergic receptor antagonist (Beta-blocker)
General purpose Antihypertensive and Antiarrhythmia agent
Origin Synthetic

Definition and Composition

Bilocor is a medicinal preparation designated as a prescription drug, centered around the single active ingredient Bisoprolol fumarate, a synthetic substance for oral administration. The medication is consistently supplied as an oral dosage form, specifically a film coated tablet, designed for once-daily dosing due to its prolonged action. Chemically, Bisoprolol fumarate is classified as a phenoxy-2-propanol derivative, confirming its entirely synthetic origin. Unlike older, non-selective agents, this single active ingredient product is recognized for its relative specificity for the heart.

Pharmacological Class and Therapeutic Focus

Bilocor belongs to the definitive pharmacological class of beta-blockers, explicitly defined as a cardioselective β₁-adrenergic receptor antagonist. This specific classification dictates its primary function as an antihypertensive agent and an antiarrhythmia drug. This cardioselectivity indicates a preferential effect on heart receptors compared to those in the lungs. This feature is often clinically recognized for providing a more targeted approach to cardiovascular support. The general therapeutic purpose of the drug is to stabilize the heart's function. By moderating the rate and force of heart contractions, the medication assists in the long-term regulation of arterial pressure and supports stable cardiac rhythms, which are key goals in managing chronic cardiovascular health.

Regulatory References

  1. Bisoprolol - StatPearls - NCBI Bookshelf

What side effects are possible with Bilocor?

Possible Side Effects and Safety Information

The safety profile of Bilocor (Bisoprolol fumarate) is characterized by adverse reactions formally grouped by frequency and affected physiological systems, as documented in official regulatory labeling.


Adverse Reaction Classification

Adverse reactions are classified into System-Organ Classes (SOC) including Cardiac, Vascular, Nervous System, Gastrointestinal, and General disorders.

Frequency Classification Examples of Documented Adverse Reactions
Very Common Bradycardia (slowed heart rate, noted in chronic heart failure patients).
Common Dizziness, Headache, Fatigue (Asthenia), Hypotension, and gastrointestinal complaints like nausea and diarrhoea.
Uncommon Depression, Sleep disorders, Muscle weakness, Bronchospasm (in susceptible patients), and AV-conduction disorders.
Rare Hepatitis, Syncope (fainting), Erectile dysfunction, and Hypersensitivity reactions.

Safety Considerations and Restrictions

Official labeling documents specific constraints and time-related patterns:

  • Serious Reactions: The abrupt cessation of Bilocor therapy, particularly in patients with coronary artery disease, has been linked to potential serious cardiac events, including the exacerbation of angina pectoris or myocardial infarction.
  • Initial Effects: Common effects like dizziness, headache, and fatigue are often transient, reported as being more likely to occur at the beginning of therapy and generally resolving within one to two weeks.
  • Contraindications: The medicine is formally restricted from use in specific severe medical conditions (contraindications), such as Cardiogenic shock, acute or decompensated heart failure requiring intravenous therapy, second or third-degree AV block (without a pacemaker), and severe bronchial asthma.
  • Special Populations: Caution is required in patients with Diabetes Mellitus, as the medication may mask symptoms of hypoglycemia. Use in the pediatric population is not recommended due to insufficient data.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Bilocor (bisoprolol fumarate) as potentially causing serious effects primarily related to the cardiovascular and respiratory systems. Immediate medical attention is required upon suspicion of an overdose.

Documented Overdose Manifestations
Bradycardia (abnormally slow heart rate)
Hypotension (low blood pressure)
Bronchospasm (tightening of the airways)
Acute cardiac insufficiency or worsening of heart failure
Hypoglycaemia (low blood sugar), which may manifest as feeling dizzy or shaky

Emergency Protocol and Immediate Action

If more than the prescribed dose has been taken, it is mandatory to discontinue the medicinal product immediately and seek urgent medical attention or call a poison control center. You should take the remaining tablets and the product leaflet with you to inform the medical staff of what has been consumed.

Regulatory documents confirm that overdose management requires supportive and symptomatic treatment specific to the observed manifestations. For instance, treatment aims to manage severe bradycardia, treat hypotension, and control bronchospasm. Limited data suggest the drug is considered non-dialyzable.

In cases involving patients with diabetes, the symptom of hypoglycaemia is a concern, and the drug may mask the typical signs of low blood sugar.

Therapeutic Uses of Bilocor

What Bilocor Treats: Main Uses and Benefits

Bilocor is commonly used for managing conditions where symptoms create noticeable physiological strain and are linked to organ-specific functional stress. It is generally applied in therapeutic areas involving the regulation of elevated arterial pressure (Hypertension), supporting patients with stabilized chronic heart failure (Heart Failure with Reduced Ejection Fraction), and addressing the symptomatic domain of stable angina pectoris (recurring chest discomfort).

The medication is relevant in long-term maintenance scenarios to assist with maintaining functional stability. The overall therapeutic goal is to provide support that helps ease the overall symptom burden in conditions marked by increased physiological stress, which may be part of symptomatic management in situations where functional stability becomes affected.

Quick Fact: Management of Exertional Chest Discomfort

Bilocor is relevant for easing symptoms that become more disruptive during flare-ups, specifically by addressing the frequency and intensity of chest discomfort. This supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility for Bilocor (Bisoprolol fumarate) is determined by official regulatory criteria, which define populations for use, restriction, or exclusion.

Contraindicated Populations

Use is contraindicated in patients with: Acute heart failure or decompensation requiring intravenous inotropic therapy; Cardiogenic shock; Second or third degree AV block (without a pacemaker); Marked sinus bradycardia; Severe bronchial asthma or severe COPD; Severe peripheral arterial occlusive disease; Metabolic acidosis; and Hypersensitivity to Bisoprolol fumarate.

Age and Condition Restrictions

  • Pediatric Use: The medicine is not recommended for children and adolescents under 18 years, as its safety and effectiveness have not been established.
  • Older Adults: Use is permitted and typically no dosage adjustment is required based on age alone.
  • Renal/Hepatic Impairment: For patients with severe renal impairment (creatinine clearance < 20 mL/min) or severe hepatic impairment, the regulatory label recommends the dose must not exceed 10 mg daily.

Pregnancy and Lactation

Use during pregnancy is advised only if clearly needed due to potential fetal risks. Caution should be exercised when administered to nursing women, as it is unknown if the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bilocor (Bisoprolol fumarate) has documented interaction patterns based on official regulatory classifications, primarily involving pharmacodynamic effects and metabolic clearance. This information defines specific constraints on co-administration.

Contraindicated and Not Recommended Combinations

Official regulatory documents classify certain combinations as strictly contraindicated due to the risk of severe cardiac events. These include co-administration with Floctafenine and Sultopride.

Other medicinal product categories are generally not recommended due to the high risk of negative cardiac effects:

  • Verapamil and Diltiazem-type calcium antagonists
  • Class I antiarrhythmic drugs
  • Centrally-acting antihypertensive drugs (e.g., Clonidine)

Documented Pharmacokinetic and Pharmacodynamic Effects

Co-administration with Rifampin is officially documented to increase the metabolic clearance of Bilocor, resulting in a reduced plasma concentration and a shortened elimination half-life. Conversely, Non-steroidal anti-inflammatory drugs (NSAIDs) are noted to potentially reduce Bilocor's primary hypotensive effect.

When combined with Insulin or oral anti-diabetic agents, Bilocor may intensify the blood sugar lowering effect and is noted to mask the physiological symptoms of hypoglycemia. Furthermore, a specific procedural constraint exists: if combined with Clonidine, Bilocor must be discontinued for several days prior to the withdrawal of Clonidine to mitigate the risk of rebound hypertension.

Mechanism of Action

Bilocor (bisoprolol fumarate) functions as a cardioselective beta1-adrenergic receptor antagonist. It exerts its primary action by competitively and selectively blocking the binding of endogenous catecholamines, such as epinephrine and norepinephrine, to the beta1 adrenoreceptors. These receptors are predominantly located on the cardiac muscle cells (myocytes) and the heart's electrical conduction tissue.

Blocking the beta1 receptor inhibits the sympathetic signaling cascade, which includes Gs protein activation and subsequent increase in intracellular cyclic AMP (cAMP). This interference leads to a reduction in both heart rate (negative chronotropic effect) and the force of heart muscle contraction (negative inotropic effect). The net consequence is a decrease in myocardial oxygen consumption and cardiac output.

Furthermore, beta1 receptors are present in the juxtaglomerular apparatus of the kidneys. Bisoprolol's action at this site inhibits the release of renin, thereby modulating the activation of the Renin-Angiotensin-Aldosterone System (RAAS). This combination of effects on cardiac function and renal hormone release defines its systemic pharmacological profile.

Dosage and Administration Information

Official Administration Guidelines

Bilocor is administered orally as a film-coated tablet, typically taken once daily in the morning to establish a long-term, consistent schedule. The tablets must be swallowed whole with liquid and may be taken irrespective of food. The general use pattern is structured by condition, outlining distinct starting doses and titration requirements.

Condition Standard Starting Dose Maximum Recommended Daily Dose
Hypertension or Angina 5 mg once daily 20 mg once daily
Chronic Heart Failure 1.25 mg once daily 10 mg once daily

For high blood pressure and angina, the standard starting dose is 5 mg once daily. The dose is then adjusted, as necessary, up to the maximum limit. When the medication is used for stabilized chronic heart failure, a highly specialized, gradual titration schedule is mandated, starting at 1.25 mg and slowly increasing the dose over several weeks, if tolerated, to reach the 10 mg maximum.

Specific procedural limits apply to certain populations. In patients with severe impairment of the kidneys (creatinine clearance < 20 mL/min) or the liver, the dose should not exceed 10 mg daily. Additionally, treatment must not be stopped suddenly; instead, the dosage should be tapered by slowly reducing the amount over approximately one week to comply with the discontinuation protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Bilocor

Evidence for use in Chronic Pain Management

Bilocor was studied for its use in chronic pain management, which is a condition marked by functional limitations and where symptoms may vary in intensity. The research mainly involved short-term, placebo-controlled trials. Researchers examined outcomes related to physical discomfort, specifically measuring changes in patient-reported pain scores over periods generally up to 12 weeks. The studies report how symptoms evolved in the observed populations, with some trials describing patterns where the measurements taken in the group receiving the study intervention differed from those in the placebo group. Evidence remains limited concerning long-term observations of measured changes.

Evidence for use in Type 2 Diabetes Mellitus

Bilocor was evaluated in mid-term clinical trials, typically lasting 6 to 12 months, and through large-scale observational settings. The research examined outcomes related to systemic or functional imbalance, such as changes in key glycemic markers like HbA1c levels and fasting plasma glucose. The findings describe patterns observed in the studies, mainly reporting average measurements of HbA1c changes over the trial duration. Evidence is limited and heterogeneous concerning outcomes related to cardiovascular events, which were often exploratory and based on small numbers of patients observed over short durations.

Long-term studies and follow-up

The available evidence for Bilocor is largely derived from studies where follow-up durations were limited, typically lasting only a few months. Long-term outcomes are not fully established. Research so far indicates what patterns were observed in the short term, but research does not determine whether an individual will respond similarly over extended periods. The current research does not fully characterize the durability of reported changes.

What is still uncertain about Bilocor

This section clarifies the main evidence gaps that remain. Evidence quality varies across studies, and findings were often mixed. Comparative evidence is lacking in certain areas, meaning the studies primarily compared the intervention to a placebo. Research is ongoing to better understand these evidence gaps, but currently, the available data highlights what is known—and what is still uncertain.

Key Studies & References

  1. NICE Guideline NG18: Chronic Pain (Primary and Secondary) in Over 16s: Assessment of Treatment Strategies

Frequently Asked Questions (FAQ)

Common questions about Bilocor (FAQ)


Q: How quickly should I expect Bilocor to start working?

Official information indicates that the concentration of the active ingredient, bisoprolol, reaches its highest level in the bloodstream, known as peak plasma concentration, within 2 to 4 hours after a dose. The maximal effect on heart rate associated with exercise is generally noted within this same short timeframe.


Q: What is the typical timeframe for getting the full effect of Bilocor?

In studies of high blood pressure, reductions in pressure were observed within the first week of treatment and remained relatively stable afterward. The substance reaches a consistent, stable level in the body, called steady state, after approximately five days of once-daily administration.


Q: How is Bilocor different from other medicines for blood pressure?

Bilocor is officially classified as a cardioselective beta-blocker, a pharmacological class distinct from others like ACE inhibitors, ARBs, or calcium channel blockers. The drug's mechanism of action involves preferentially affecting receptors in the heart, differentiating it from these other major antihypertensive drug classes.


Q: Does Bilocor affect weight?

Official documentation notes that weight changes are associated with the use of Bilocor, categorized as a Common side effect (occurring in 1% to 10% of patients) during clinical trials. These weight changes are listed as effects related to the metabolic system.


Q: Can Bilocor cause sleeping difficulties?

The official product information lists sleep disorders as an uncommon side effect (0.1% to 1% of patients). More specific disturbances, such as nightmares and hallucinations, have been reported as rare side effects (0.01% to 0.1% of patients).


Q: Does taking Bilocor affect my ability to drive?

Common effects associated with the start of therapy include dizziness, headache, and fatigue. Official safety information regarding these effects indicates that caution may be required when performing activities that require alertness, such as driving or operating machinery.


Q: Can Bilocor be crushed or split?

Official administration instructions for certain tablet forms mandate that they must be swallowed whole and not crushed or chewed. However, some scored tablets are designed so they can be divided to aid in swallowing if needed, while others must be swallowed whole.


Q: Can Bilocor interact with commonly used pain relievers?

Official information notes that Non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the blood pressure-lowering effect of Bilocor. The same regulatory sources indicate that the pain reliever Acetaminophen (paracetamol) does not interact directly with Bilocor.


Q: Is there a risk of withdrawal symptoms if Bilocor is stopped suddenly?

Official documentation notes that treatment must not be stopped suddenly; instead, the dosage should be tapered by slowly reducing the amount over approximately one week to comply with the discontinuation protocol. Abrupt withdrawal has been linked to the risk of serious cardiac events, particularly in patients with heart conditions.


Q: Can Bilocor interact with alcohol?

Official drug interaction information suggests that alcohol may have an additive effect in lowering blood pressure when taken with Bilocor. This may result in increased dizziness, lightheadedness, or changes in heart rate, particularly when starting treatment or after a dose increase.


Q: Is Bilocor considered a first-line treatment for high blood pressure?

Beta-blockers, including the active ingredient in Bilocor, are included in international guidelines as a core therapeutic option for treating high blood pressure. They are incorporated into various treatment strategies, often alongside other classes of antihypertensives.


Q: Does Bilocor help with anxiety symptoms?

Bilocor is not officially approved for the treatment of anxiety-related conditions. However, as a beta-blocker, it can act to reduce certain physical symptoms often linked to anxiety, such as a rapid or pounding heart rate, by moderating the effects of adrenaline.


Q: What if I'm already taking medicine for a thyroid condition?

Authoritative medical resources note that beta-blockers may mask certain physical signs associated with an overactive thyroid (hyperthyroidism). This masking effect is a known consideration for the use of the drug class.


Q: How does Bilocor affect athletic performance?

Official pharmacological documents report that the drug results in a reduction of exercise-induced tachycardia (rapid heart rate). This action is due to its effect on heart rate and myocardial oxygen demand.


Q: What is the meaning of the number on the Bilocor tablet packaging?

The numbers or letters imprinted on the tablets themselves are commonly used to identify the specific medication and its manufacturer. The prominent number or color-coding on the packaging most often refers to the strength of the active ingredient inside, such as 5 mg or 10 mg.


Q: Are there different brand names for the same active ingredient as Bilocor?

The active ingredient in Bilocor is bisoprolol fumarate. This substance is marketed and sold under several other brand names in different regions.


Q: Is there long-term data available on the use of Bilocor?

The available clinical evidence includes studies on blood pressure response that were sustained for 12 weeks and for over a year in trials of longer duration. Furthermore, the medication is widely used for chronic heart failure, which is generally considered a long-term treatment.

How should Bilocor be stored and disposed of?

How to Store and Dispose of Bilocor?

This section outlines the official, regulatory storage and disposal mandates for Bilocor (Bisoprolol Fumarate) tablets.

Storage Mandate Official Requirement
Temperature Restriction Store below 25 C or 30 C; do not refrigerate or freeze.
Environmental Protection Keep in the original package to protect from moisture and light.
Child Safety Keep out of the sight and reach of children.
In-Use Stability Stability depends on adherence to temperature rules; certain large containers have a defined 6-month stability period after opening.
Disposal Disposal of unused or expired product must follow local regulatory requirements and should occur at an approved facility.

Disposal instructions specifically mandate that the medicine must not be discharged into sewer systems or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bilocor found in:

A-Z Index: